A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy

Norihiro Imai, Kinichi Takeda, Setsuo Utsunomiya, Masahiro Taga, Noboru Kawata, Takashi Ikeda, Yoshitaka Mizutani, Ken Hirose, Tetsuya Ishikawa, Shonen Yoshida

Research output: Contribution to journalArticle

Abstract

A 52-year-old woman with a chief complaint of epigastric distress was diagnosed as having pancreatic cancer with multiple liver metastases. After insertion of a metallic stent for biliary stenosis, combination therapy of gemcitabine (GEM) and adoptive immune cell therapy (AICT) was initiated. GEM 1,000 mg/m2 was administered on day 1, 8 and 15 every 4 weeks, while AICT using MUC1 peptide-pulsed dendritic cells (DC) and anti-CD3-activated T lymphocytes (CAT) was given biweekly. After 6 courses of GEM and 9 courses of DC-CAT, the patient was considered to have a complete response (CR) on CT and MRI examination. CR has still been maintained by the continuous administration of GEM and CAT. The combination therapy of GEM and AICT was suggested to be effective against advanced pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)527-529
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume37
Issue number3
StatePublished - Mar 6 2010
Externally publishedYes

Fingerprint

gemcitabine
Cell- and Tissue-Based Therapy
Pancreatic Neoplasms
T-Lymphocytes
Dendritic Cells
Therapeutics
Stents
Pathologic Constriction
Neoplasm Metastasis
Peptides
Liver

Keywords

  • Dendritic cell
  • Gemcitabine
  • MUC1
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy. / Imai, Norihiro; Takeda, Kinichi; Utsunomiya, Setsuo; Taga, Masahiro; Kawata, Noboru; Ikeda, Takashi; Mizutani, Yoshitaka; Hirose, Ken; Ishikawa, Tetsuya; Yoshida, Shonen.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 37, No. 3, 06.03.2010, p. 527-529.

Research output: Contribution to journalArticle

Imai, N, Takeda, K, Utsunomiya, S, Taga, M, Kawata, N, Ikeda, T, Mizutani, Y, Hirose, K, Ishikawa, T & Yoshida, S 2010, 'A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy', Japanese Journal of Cancer and Chemotherapy, vol. 37, no. 3, pp. 527-529.
Imai, Norihiro ; Takeda, Kinichi ; Utsunomiya, Setsuo ; Taga, Masahiro ; Kawata, Noboru ; Ikeda, Takashi ; Mizutani, Yoshitaka ; Hirose, Ken ; Ishikawa, Tetsuya ; Yoshida, Shonen. / A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy. In: Japanese Journal of Cancer and Chemotherapy. 2010 ; Vol. 37, No. 3. pp. 527-529.
@article{cd9fb617fa0b4e2bbd2162833f8df9b6,
title = "A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy",
abstract = "A 52-year-old woman with a chief complaint of epigastric distress was diagnosed as having pancreatic cancer with multiple liver metastases. After insertion of a metallic stent for biliary stenosis, combination therapy of gemcitabine (GEM) and adoptive immune cell therapy (AICT) was initiated. GEM 1,000 mg/m2 was administered on day 1, 8 and 15 every 4 weeks, while AICT using MUC1 peptide-pulsed dendritic cells (DC) and anti-CD3-activated T lymphocytes (CAT) was given biweekly. After 6 courses of GEM and 9 courses of DC-CAT, the patient was considered to have a complete response (CR) on CT and MRI examination. CR has still been maintained by the continuous administration of GEM and CAT. The combination therapy of GEM and AICT was suggested to be effective against advanced pancreatic cancer.",
keywords = "Dendritic cell, Gemcitabine, MUC1, Pancreatic cancer",
author = "Norihiro Imai and Kinichi Takeda and Setsuo Utsunomiya and Masahiro Taga and Noboru Kawata and Takashi Ikeda and Yoshitaka Mizutani and Ken Hirose and Tetsuya Ishikawa and Shonen Yoshida",
year = "2010",
month = "3",
day = "6",
language = "English (US)",
volume = "37",
pages = "527--529",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy

AU - Imai, Norihiro

AU - Takeda, Kinichi

AU - Utsunomiya, Setsuo

AU - Taga, Masahiro

AU - Kawata, Noboru

AU - Ikeda, Takashi

AU - Mizutani, Yoshitaka

AU - Hirose, Ken

AU - Ishikawa, Tetsuya

AU - Yoshida, Shonen

PY - 2010/3/6

Y1 - 2010/3/6

N2 - A 52-year-old woman with a chief complaint of epigastric distress was diagnosed as having pancreatic cancer with multiple liver metastases. After insertion of a metallic stent for biliary stenosis, combination therapy of gemcitabine (GEM) and adoptive immune cell therapy (AICT) was initiated. GEM 1,000 mg/m2 was administered on day 1, 8 and 15 every 4 weeks, while AICT using MUC1 peptide-pulsed dendritic cells (DC) and anti-CD3-activated T lymphocytes (CAT) was given biweekly. After 6 courses of GEM and 9 courses of DC-CAT, the patient was considered to have a complete response (CR) on CT and MRI examination. CR has still been maintained by the continuous administration of GEM and CAT. The combination therapy of GEM and AICT was suggested to be effective against advanced pancreatic cancer.

AB - A 52-year-old woman with a chief complaint of epigastric distress was diagnosed as having pancreatic cancer with multiple liver metastases. After insertion of a metallic stent for biliary stenosis, combination therapy of gemcitabine (GEM) and adoptive immune cell therapy (AICT) was initiated. GEM 1,000 mg/m2 was administered on day 1, 8 and 15 every 4 weeks, while AICT using MUC1 peptide-pulsed dendritic cells (DC) and anti-CD3-activated T lymphocytes (CAT) was given biweekly. After 6 courses of GEM and 9 courses of DC-CAT, the patient was considered to have a complete response (CR) on CT and MRI examination. CR has still been maintained by the continuous administration of GEM and CAT. The combination therapy of GEM and AICT was suggested to be effective against advanced pancreatic cancer.

KW - Dendritic cell

KW - Gemcitabine

KW - MUC1

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=79960819838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960819838&partnerID=8YFLogxK

M3 - Article

C2 - 20332697

AN - SCOPUS:79960819838

VL - 37

SP - 527

EP - 529

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 3

ER -